Chimerix (CMRX) Projected to Post Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Chimerix to post earnings of ($0.26) per share and revenue of $0.31 million for the quarter.

Chimerix Stock Performance

NASDAQ:CMRX opened at $5.04 on Tuesday. The company has a market capitalization of $453.28 million, a PE ratio of -5.36 and a beta of 0.35. The company has a 50 day simple moving average of $3.96 and a two-hundred day simple moving average of $2.11. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last quarter. 13.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CMRX. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Tuesday, February 18th. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective (up previously from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.